Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $46.43.

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research report on Friday, May 17th.

Outlook Therapeutics Stock Performance

Shares of NASDAQ OTLK opened at $8.56 on Monday. The company’s fifty day moving average price is $7.68 and its 200 day moving average price is $8.09. Outlook Therapeutics has a 1 year low of $4.00 and a 1 year high of $34.80. The company has a market capitalization of $200.39 million, a PE ratio of -0.75 and a beta of 0.71.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.67). On average, equities analysts expect that Outlook Therapeutics will post -4.08 EPS for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

A hedge fund recently bought a new stake in Outlook Therapeutics stock. LVW Advisors LLC bought a new stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 47,730 shares of the company’s stock, valued at approximately $352,000. LVW Advisors LLC owned about 0.20% of Outlook Therapeutics as of its most recent SEC filing. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.